Endoscopic Stricturotomy Versus Endoscopic Balloon Dilatation in Patients With Crohn's Disease and Symptomatic Small Bowel Stricture

Crohn Disease Clinical Trial

— DESTRESS  

Official title:

Randomized Trial of Endoscopic Stricturotomy Versus Endoscopic Balloon Dilatation in Patients With Crohn's Disease and Symptomatic Small Bowel Stricture

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05009212
• Other study ID #: 2021ZSLYEC-243
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2021
• Est. completion date: December 31, 2025

Study information

• Verified date: August 2021
• Source: Sixth Affiliated Hospital, Sun Yat-sen University
• Contact: Qin Guo, MD
• Phone: +86-20-38663423
• Email: guoq83[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Stenosis is one of the most frequent complications in patients with Crohn's disease (CD). In particular, CD patients with intestinal strictures are often faced with short bowel syndrome after repeated or extensive surgical resection.

Endoscopic management shows good efficacy and safety in the treatment of strictures in CD patients. The European Crohn's and Colitis Organisation (ECCO) guideline recommended that endoscopic balloon dilatation is suitable to treat short [<5 cm] strictures of the terminal ileum in CD. Recently, Lan et al. reported that endoscopic stricturotomy appeared to be more effective in treating CD patients with anastomotic stricture than endoscopic balloon dilatation.

However, there is no prospective clinical studies evaluating the efficacy and safety of endoscopic stricturotomy in the treatment of fibrostenotic Crohn's disease. The trial aims to compare the efficacy and safety of endoscopic stricturotomy with endoscopic balloon dilation in the treatment of small bowel stricture in patients with Crohn's Disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Subjects had been diagnosed with CD for at least 3 months prior to screening, and the diagnosis of CD had clinical findings and endoscopic, imaging evidence, and was supported by histopathology reports

2. Subject is in remission from CD (CDAI score < 150)

3. Subjects had clinical findings of multiple fibrotic strictures of the bowel with obstruction and imaging evidence, and/or endoscopic evidence

4. Subjects had = 3 small bowel strictures (length < 5 cm) from duodenum to rectum and < 50 cm distance between strictures

5. Study process prior to initiation, the subject or subject's legal representative (if applicable) signed and dated a written informed consent form or any required documentation of privacy authorization

6. Female subjects who remained sexually and of childbearing potential with an ungerminated male partner, consented to adequate routine contraception throughout the study period starting with signing informed consent

Exclusion Criteria:

1. At the initial screening visit, subject presented with enterocutaneous fistula, abdominal abscess, evidence of gastrointestinal bleeding

2. Subjects were in active CD (CDAI score = 150)

3. The subject had inflammatory activity in the stenotic bowel (as judged by a combination of blood inflammatory indices, endoscopy, ultrasound and imaging)

4. Presence of ileostomy, colostomy

5. Subjects had a history or evidence of adenomatous colonic polyps that had not been resected or had a history or evidence of dysplasia of the colonic mucosa, including low - or high-grade dysplasia, and an undiagnosed type of dysplasia

6. Subjects had suspected or confirmed ulcerative colitis, undiagnosed types of colitis, ischemic colitis, radiation enteritis, colitis associated diverticular disease, or microscopic colitis

7. Subjects had evidence of active infection during the screening period

8. Subject has active tuberculosis

9. Subjects with any defined inborn or acquired immunodeficiency (e.g., common various immunodeficiencies, human immunodeficiency virus [HIV] infection, organ transplantation)

10. Subjects had a clinically significant infection (e.g., pneumonia, pyelonephritis) or an ongoing chronic infection within 30 days prior to screening

11. The subject suffered from any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immune, endocrine / metabolic or other medical condition that, in the opinion of the investigator, would interfere with the outcome of the study or jeopardize the safety of the subject

12. The subject's medical history included malignancy

13. Subjects had abnormal laboratory results for any of the following during screening:

hemoglobin < 5 g / dl; white blood cell (WBC) count < 3 ×10E9 / L; platelet count < 100 × 10E9 / L or > 1200 × 10E9 / L; alanine transaminase (ALT) or aspartate transaminase (AST) > 3 × upper limit of normal (ULN), and serum creatinine > 2 × ULN.

14. Subjects were unable to attend all study visits or comply with study flow plans female subjects were pregnant prior to study enrollment, during study enrollment, or plan to donate eggs during these time periods

15. Subjects were forced to consent to participate in the study

16. Investigators considered the subject unsuitable for endoscopic treatment

Related Conditions & MeSH terms

• Constriction, Pathologic
• Crohn Disease
• Endoscopy, Gastrointestinal
• Stricture; Bowel

Intervention

Procedure:
• Endoscopic stricturotomy
Endoscopic stricturotomy for bowel stricture (<5 cm)
• Endoscopic balloon dilatation
Endoscopic balloon dilatation for bowel stricture (<5 cm)

Locations

Country	Name	City	State
China	The Sixth Affiliated Hospital, Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sixth Affiliated Hospital, Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surgery-free survival	Percentage of patients who do not receive surgical intervention for obstruction recurrence	52 weeks
Secondary	Endoscopic intervention-free survival	Percentage of patients who do not receive endoscopic intervention for obstruction recurrence	52 weeks
Secondary	Intervention-free survival	Percentage of patients who do not receive surgical or endoscopic intervention for obstruction recurrence	Week 52
Secondary	Technical success rate	The passage of endoscope without resistance	Week 0
Secondary	Obstructive score change	Obstructive score (scaling from 0 to 6, higher scores mean a worse outcome) change compared to baseline	Week 8, 16, 26, 52
Secondary	Crohn's Disease Activity Index (CDAI) score change	Higher scores mean a worse outcome for CDAI score	Week 8, 16, 26, 52
Secondary	Inflammatory Bowel Disease Questionnaire (IBDQ) score reduction	Higher scores mean a better outcome for IBDQ score	Week 8, 16, 26, 52
Secondary	Adverse event rate	Percentage of adverse events	Week 52
Secondary	Total cost	Total cost for intervention	Week 52